# CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

> **NCT02500602** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 144 (actual)

## Conditions studied

- Posttraumatic Stress Disorder
- Alcohol Use Disorders

## Interventions

- **DRUG:** doxazosin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02500602
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2019-12-16
- **Final completion:** 2019-12-16
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500602, "CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02500602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*